SNRNP200 (Small Nuclear Ribonucleoprotein 200)
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SNRNP200 (Small Nuclear Ribonucleoprotein 200)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SNRNP200</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>BRR2, U4/U6.U5 tri-snRNP-associated protein 200</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>23052</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>601680</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000154473</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O43822</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,046 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~230 kDa</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Rod photoreceptors</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Cone photoreceptors</td>
<td>High</td>
</tr>
<tr>
<td class="label">Bipolar cells</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Ganglion cells</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Function</td>
</tr>
<tr>
<td class="label">PRPF8</td>
<td>U5 snRNP, spliceosome catalytic core</td>
</tr>
<tr>
<td class="label">PRPF6</td>
<td>U5 snRNP, tri-snRNP stability</td>
</tr>
<tr>
<td class="label">PRPF31</td>
<td>U4 snRNP</td>
</tr>
<tr>
<td class="label">SNRPB</td>
<td>Core snRNP proteins</td>
</tr>
<tr>
<td class="label">SART3</td>
<td>Tri-snRNP recycling</td>
</tr>
<tr>
<td class="label">BRCA2</td>
<td>DNA repair, splicing regulation</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>ALS protein, RNA binding</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>ALS protein, RNA processing</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Association</td>
</tr>
<tr>
<td class="label">Retinitis Pigmentosa</td>
<td>Primary cause</td>
</tr>
<tr>
<td class="label">Cone-Rod Dystrophy</td>
<td>Cause</td>
</tr>
<tr>
<td class="label">Amyotrophic Lateral Sclerosis</td>
<td>Modifier</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Potential modifier</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
SNRNP200 (Small Nuclear Ribonucleoprotein 200), also known as U4/U6.U5 tri-snRNP-associated protein 200 or BRR2 (Bad Response to Refrigeration 2 in yeast), is a key component of the U4/U6.U5 tri-snRNP complex that plays an essential role in spliceosome activation. SNRNP200 is a member of the DNA/RNA helicase family and functions as the catalytic engine for RNA duplex unwinding during the splicing reaction. The protein is highly conserved across eukaryotes and is essential for viability in all organisms examined[@agafonov2019].
In humans, SNRNP200 is ubiquitously expressed with particularly high levels in the retina and nervous system. Mutations in SNRNP200 are causative for retinitis pigmentosa (RP), a hereditary retinal degeneration leading to progressive vision loss. Additionally, altered SNRNP200 function has been implicated in Amyotrophic Lateral Sclerosis (ALS), where spliceosomal dysfunction is a recognized pathological hallmark. The protein's fundamental role in RNA splicing makes it a critical node in understanding how splicing defects contribute to neurodegeneration[@chen2018].
Gene and Protein Structure
Gene Organization
The SNRNP200 gene is located on chromosome 2q11.2 in humans, spanning approximately 36 kb of genomic DNA. The gene consists of 45 exons encoding a protein of 2,046 amino acids with a molecular weight of approximately 230 kDa.
Protein Domain Architecture
SNRNP200 is one of the largest spliceosomal proteins:
N-terminal Region (1-500 aa): Contains multiple NQQ repeats and regulatory domains
- NQQ (Asn-Gln-Gln) repeats of unknown function
- DExD-box helicase domain (N-terminal portion)
Helicase Core Region (500-1500 aa): Contains the canonical helicase domains
- Motif I (Walker A/PP-loop): ATP binding (GxxxxGK[S/T])
- Motif II (Walker II): DEAH box ATP hydrolysis (DEAH)
- Motif III: DNA/RNA helicase activity
- Motif IV: DNA/RNA binding
- Motif V: ATP sensing
- Motif VI: ATP hydrolysis and clamp
C-terminal Region (1500-2046 aa): Contains C-terminal helicase domain
- Second helicase cassette
- Regulatory CTD (C-terminal domain)
- Multiple RG (Arg-Gly) repeats
The C-terminal region contains an "RNA helicase-inhibited" conformation that regulates activity.
Normal Physiological Function
Spliceosome Function
SNRNP200 is the catalytic helicase of the spliceosome:
Role in Spliceosome Activation:
- Component of the U4/U6.U5 tri-snRNP complex
- Unwinds the U4/U6 snRNA duplex during spliceosome activation
- Enables the catalytic steps of pre-mRNA splicing
- Catalyzes spliceosome disassembly after reaction completion
Mechanism:Mermaid diagram (expand to render)
Splicing Reactions Catalyzed:
- 5' splice site cleavage
- Lariat formation
- 3' splice site cleavage
- Exon ligation
Cellular Functions
Beyond splicing, SNRNP200 participates in:
mRNA Processing:
- Quality control of splicing
- Alternative splicing regulation
- snRNA maturation
Ribonucleoprotein Biogenesis:
- snRNP assembly and maturation
- snRNP trafficking
Cellular Stress Response:
- Involved in stress granule formation
- Splicing changes under stress conditions
Role in Neurodegenerative Diseases
Retinitis Pigmentosa
SNRNP200 is one of the most common genes causing retinitis pigmentosa:
Genetic Association:
- Over 100 RP-associated variants identified
- Primarily autosomal dominant inheritance
- De novo variants also observed
Pathogenic Mechanisms:
- Loss-of-function mechanism
- Impaired spliceosome function in photoreceptors
- Photoreceptor-specific vulnerability
RP Phenotype:
- Progressive rod photoreceptor degeneration
- Night blindness as first symptom
- Peripheral vision loss
- Tunnel vision progression
- Cone degeneration in later stages
Variant Types:
- Missense variants (most common)
- Splice-site variants
- Nonsense variants
- Frameshift variants
Amyotrophic Lateral Sclerosis (ALS)
SNRNP200 involvement in ALS is emerging:
Splicing Dysregulation:
- Global splicing defects in ALS motor neurons
- SNRNP200 expression altered in ALS tissue
- Spliceosome dysfunction contributes to disease
Mechanistic Links:
- TDP-43 pathology affects spliceosome function
- SNRNP200 interactions with ALS proteins
- Impaired RNA processing contributes to neurodegeneration
Evidence:
- Post-mortem ALS spinal cord shows splicing alterations
- SNRNP200 genetic variants identified in ALS patients
- Cellular models show SNRNP200 dysfunction contributes to pathology
Alzheimer's Disease
Emerging evidence for AD involvement:
- Splicing defects observed in AD brains
- SNRNP200 expression changes in AD
- Spliceosomal dysfunction contributes to pathology
Expression Patterns
Brain Distribution
SNRNP200 exhibits widespread expression in the brain:
Retina Distribution
Particularly high expression in the retina:
Subcellular Localization
- Nuclear speckles: Primary localization
- Nucleolus: Low levels
- Cytoplasm: Minimal
- Spliceosome: Component of spliceosomal complex
Interacting Partners
Spliceosomal Proteins
snRNAs
- U1 snRNA
- U2 snRNA
- U4 snRNA
- U5 snRNA
- U6 snRNA
Therapeutic Potential
Drug Development Targets
SNRNP200 is a potential therapeutic target:
Retinitis Pigmentosa:
- Gene replacement therapy (AAV vectors)
- Antisense oligonucleotide therapy for splice-site variants
- Small molecule approaches to enhance spliceosome function
ALS:
- Modulating spliceosome activity
- Targeting downstream splicing defects
- Gene therapy approaches
Biomarker Potential
SNRNP20 as a biomarker:
- Retinal imaging for RP progression
- Blood splicing signatures for ALS
- Genetic testing for at-risk individuals
Clinical Relevance
Disease Associations
Genetic Variants
Retinitis Pigmentosa:
- p.R998C: Common variant
- p.S1087L: Founder mutation in some populations
- p.P2015L: Pathogenic variant
- Various splice-site variants
ALS:
- Rare missense variants identified
- Contribution to disease risk
Summary
SNRNP200 is the catalytic helicase of the spliceosome, essential for pre-mRNA splicing. Mutations in SNRNP200 cause retinitis pigmentosa, making it one of the most important genes in hereditary retinal degeneration. Spliceosomal dysfunction is also recognized in ALS and other neurodegenerative diseases. Understanding SNRNP200's function and developing therapies targeting its activity represent important directions for treating these disorders.
See Also
- [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Spliceosome and Neurodegeneration](/mechanisms/spliceosome-neurodegeneration)
- [Alternative Splicing](/mechanisms/alternative-splicing-neurodegeneration)
- [Photoreceptor Degeneration](/mechanisms/photoreceptor-degeneration)
- [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
References
[Agafonov DE, et al., Spliceosome and SNRNP200 mechanism (2019)](https://pubmed.ncbi.nlm.nih.gov/31748742/)
[Akanuma T, et al., SNRNP200 variants in retinitis pigmentosa (2019)](https://pubmed.ncbi.nlm.nih.gov/30753551/)
[Chen Y, et al., Spliceosome mutations in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29368169/)
[Liu Y, et al., RNA splicing in neurodegeneration and retinal disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30608567/)
[Vaser R, et al., SNRNP200 in neuronal function (2019)](https://pubmed.ncbi.nlm.nih.gov/31849624/)
[Tang L, et al., Spliceosomal proteins in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/31916078/)
[Wang Y, et al., Genetics of retinitis pigmentosa (2020)](https://pubmed.ncbi.nlm.nih.gov/32109472/)
[Zhang L, et al., Spliceosome dysfunction in ALS (2019)](https://pubmed.ncbi.nlm.nih.gov/31727885/)
[Kondo K, et al., RNA splicing as therapeutic target (2019)](https://pubmed.ncbi.nlm.nih.gov/31248759/)
[Liu Y, et al., SNRNP200 and the spliceosome (2020)](https://pubmed.ncbi.nlm.nih.gov/32212734/)
[Gao Y, et al., Splicing factor mutations in ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32027916/)
[Pan Q, et al., Deep sequencing of spliceosome in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29539423/)
[Song J, et al., Spliceosome proteins as biomarkers (2019)](https://pubmed.ncbi.nlm.nih.gov/30697868/)
[Hutton J, et al., Retinitis pigmentosa treatments (2020)](https://pubmed.ncbi.nlm.nih.gov/32502604/)
[Blencowe BJ, et al., The spliceosome as ribonucleoprotein machine (2019)](https://pubmed.ncbi.nlm.nih.gov/31039527/)
[Yoshida M, et al., RNA splicing in retinitis pigmentosa (2020)](https://pubmed.ncbi.nlm.nih.gov/32367352/)
[Cvajic G, et al., Spliceosomal mutations in neurological disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32019856/)
[Zhang Z, et al., Therapeutic targeting of RNA splicing (2021)](https://pubmed.ncbi.nlm.nih.gov/33408405/)
[Roach L, et al., RNA splicing in photoreceptor disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31176638/)
[Li Z, et al., SNRNP200 variants in cone-rod dystrophy (2021)](https://pubmed.ncbi.nlm.nih.gov/33848821/)